The recent authorization of ZYN oral nicotine pouches by the U.S. Food and Drug Administration (FDA) marks a major step forward in tobacco harm reduction. By recognizing these pouches as a better alternative to smoking, the FDA has reinforced the importance of smoke-free options in the fight against smoking. This decision should prompt Pakistan to reconsider its stance on oral nicotine pouches, which currently exist in a regulatory gray area despite their potential to reduce smoking rates.
Pakistan has one of the highest smoking rates globally, with an estimated 31 million smokers. The consequences are dire – over 160,000 deaths annually are attributed to smoking, according to the World Health Organization (WHO). The financial burden is equally alarming. In 2019, Pakistan spent an estimated USD 3.85 billion on smoking-related diseases, including lung cancer, heart disease, and chronic obstructive pulmonary disease (COPD). The country’s healthcare system is already stretched thin, making it imperative to explore effective alternatives.
Unlike smoking, nicotine pouches deliver nicotine without combustion, the primary cause of smoking-related illnesses. These products offer an option for adult smokers who are unable or unwilling to quit smoking but seek a better option. The FDA’s authorization of ZYN oral nicotine pouches underscores the importance of regulatory oversight to ensure product quality, safety, and responsible marketing.
In contrast, Pakistan has yet to establish clear regulations for nicotine pouches. While these products are available in the market, their unregulated status leaves consumers uncertain about product quality and safety. The lack of oversight also means missed opportunities for public awareness and harm-reduction campaigns. A well-defined regulatory framework would ensure nicotine pouches are properly labeled, responsibly marketed, and widely accessible to adult smokers.
This article is written by Danial Hashmi.